About US
Contact us
-
Bad news for AbbVie: Humira copies expected to rack up biggest biosim salesHere's something AbbVie ($ABBV) doesn't want to hear: Industry watchers expect biosimilars for its top moneymakerHumirato be the most successful copycat biologics launched in the U.S. and Europe. Tha2015/6/17
-
Drug price hawk CVS Health and the case of the $44,000 nutrition supplementCVS Health ($CVS) may be staring down pricey hep C drugs and forthcoming PCSK9 meds, but capsules of powdered resveratrol? Not so much. The pharmacy benefits manager recently approved a $44,000 claim2015/6/17
-
Branded pharma worries, generics makers cheer as trade pact hits snag in CongressTheTrans-Pacific Partnershiptook it on the chin Friday when the U.S. House voted against a key assistance program for workers displaced by global trade. That move throws a wrench into U.S. efforts to2015/6/16
-
You want to quash 'Low-T' overprescription, FDA? Quash DTC ads, experts urgeAfter warning that casual use oftestosterone medscan cause heart attack and stroke, theFDAhas finally put its foot down to curb overprescribing of the drugs. But some say the agency needs to go furthe2015/6/16
-
Are CV studies worth it for diabetes meds? After Merck and Sanofi's recent successes, some say noEarlier this week, diabetes drugmakers Merck ($MRK) and Sanofi ($SNY) rolled out data showing their meds--Januvia and Lyxumia, respectively--passed heart safety tests, turning up no red flags in postm2015/6/15
-
Consumer group demands FDA correct 'compounded mistake' on Vanda's Hetlioz labelThe FDA has already admitted that it made a mistake with its initial approval letter forVanda Pharmaceuticals' sleep disorder drug early last year, a consumer advocacy group says. And now, that group2015/6/15
-
Second investigator linked to GSK bribery scandal released from Chinese prisonEarlier this week, Chinese authorities released Peter Humphrey--a private eye linked to GlaxoSmithKline's ($GSK) 2013 bribery scandal--from local prison after a court reduced his sentence by about 7 m2015/6/12
-
Pfizer in quick succession turns aside second lawsuit alleging Zoloft birth defects tiesJust weeks after winning the first case to go to trial that accused Pfizer of hiding birth defect risks for the children of women who took the antidepressant Zoloft during pregnancy, the pharma giant2015/6/12
-
Leaked TPP document shows pharma still angling for pricing influencePresident Barack Obama The Obama administration is backing off of drug-price protections in the bigTrans-Pacific Partnershiptreaty now under negotiation,The New York Timesreports. But U.S.2015/6/11
-
Want to take on Gilead in hep C, Merck? Try niche marketing, game theory expert saysIn game theory, the so-called "Judo strategy" involves using the size and strength of opponents against them. And that's exactly what Yale Professor Barry Nalebuff thinks Merck ($MRK) should employ wh2015/6/11